Ascletis

Pharma

Enhertu, Akeso, Fujifilm-Regeneron—Fierce Pharma Asia

Enhertu delivered a positive readout in first-line breast cancer. Akeso's ivonescimab bagged another phase 3 win. Fujifilm signed a 10-year deal with Regeneron.

Angus Liu Apr 25, 2025 8:45am

Novo, Merck, Hengrui-Elevar—Fierce Pharma Asia

Mar 28, 2025 9:28am

Novo Nordisk, AstraZeneca, Ono—Fierce Pharma Asia

Feb 21, 2025 8:45am

Eisai, Carvykti, Ozempic biosimilar—Fierce Pharma Asia

Apr 5, 2024 8:25am